SciELO - Scientific Electronic Library Online

vol.137 número7Análisis crítico de un artículo: ¿Sirve reducir los niveles de homocisteinemia en los pacientes con insuficiencia renal avanzada? índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados




Links relacionados


Revista médica de Chile

versão impressa ISSN 0034-9887


CRUZ U, Ricardo  e  LETELIER S, Luz María. Critically appraised article: Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis. Rev. méd. Chile [online]. 2009, vol.137, n.7, pp.986-989. ISSN 0034-9887.

Context: Recent reports of serious adverse events with rosiglitazone use have raised questions about whether the evidence of harm justifies its use for treatment of type 2 diabetes. Objective: To systematically review the long-term cardiovascular risks of rosiglitazone, including myocardial infarction, heart failure, and cardiovascular mortality. Data sources: We searched MEDLINE, the GlaxoSmithKline clinical trials register, the US Food and Drug Administration Web site, and product information sheets for randomized controlled trials, systematic reviews, and meta-analyses published in English through May 2007. Study selection: Studies were selected for inclusion if they were randomized controlled trials of rosiglitazone for prevention or treatment of type 2 diabetes, had at least 12 months of follow-up, and monitored cardiovascular adverse events and provided numerical data on all adverse events. Four studies were included after detailed screening of 140 trials for cardiovascular events. Data extraction: Relative risks (RRs) of myocardial infarction, heart failure, and cardiovascular mortality were estimated using a fixed-effects meta-analysis of 4 randomized controlled trials (n =14.291, including 6.421 receiving rosiglitazone and 7.870 receiving control therapy with a duration of follow-up of 1-4 years). Results: Rosiglitazone significantly increased the risk of myocardial infarction (n =94/6421 vs. 83/7870; RR, 1.42; 95% confidence interval fCIJ, 1.06-1.91; P =.02) and heart failure (n =102/6.421 vs. 62/7.870; RR, 2.09; 95% CI, 1.52-2.88; P k.001) without a significant increase in risk of cardiovascular mortality (n =59/6.421 vs. 72/7.870; RR, 0.90; 95% CI, 0.63-1.26; P =.53). There was no evidence of substantial heterogeneity among the trials for these end points (1(2) =0% for myocardial infarction, 18% for heart failure, and 0% for cardiovascular mortality). Conclusion: Among patients with impaired glucose tolerance or type 2 diabetes, rosiglitazone use for at least 12 months is associated with a significantly increased risk of myocardial infarction and heart failure, without a significantly increased risk of cardiovascular mortality.

        · texto em Espanhol     · Espanhol ( pdf )


Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons